CA3080128A1 - Composes de selenogalactoside pour le traitement de troubles de la resistance systemique a l'insuline et leur utilisation - Google Patents

Composes de selenogalactoside pour le traitement de troubles de la resistance systemique a l'insuline et leur utilisation Download PDF

Info

Publication number
CA3080128A1
CA3080128A1 CA3080128A CA3080128A CA3080128A1 CA 3080128 A1 CA3080128 A1 CA 3080128A1 CA 3080128 A CA3080128 A CA 3080128A CA 3080128 A CA3080128 A CA 3080128A CA 3080128 A1 CA3080128 A1 CA 3080128A1
Authority
CA
Canada
Prior art keywords
group
substituted
heteroaryl
naphthyl
group substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3080128A
Other languages
English (en)
Inventor
Peter G. Traber
Eliezer Zomer
Deirdre SLATE
Joseph M. Johnson
Ryan George
Sharon Shechter
Raphael NIR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galectin Sciences LLC
Original Assignee
Galectin Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galectin Sciences LLC filed Critical Galectin Sciences LLC
Publication of CA3080128A1 publication Critical patent/CA3080128A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/08—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Selon des aspects, la présente invention concerne de nouveaux composés synthétiques ayant une affinité de liaison avec des protéines de galectine pour le traitement de troubles de la résistance systémique à l'insuline.
CA3080128A 2017-10-31 2018-05-11 Composes de selenogalactoside pour le traitement de troubles de la resistance systemique a l'insuline et leur utilisation Pending CA3080128A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762579343P 2017-10-31 2017-10-31
US62/579,343 2017-10-31
PCT/US2018/032321 WO2019089080A1 (fr) 2017-10-31 2018-05-11 Composés de sélénogalactoside pour le traitement de troubles de la résistance systémique à l'insuline et leur utilisation

Publications (1)

Publication Number Publication Date
CA3080128A1 true CA3080128A1 (fr) 2019-05-09

Family

ID=66332241

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3080128A Pending CA3080128A1 (fr) 2017-10-31 2018-05-11 Composes de selenogalactoside pour le traitement de troubles de la resistance systemique a l'insuline et leur utilisation

Country Status (8)

Country Link
EP (1) EP3707149A1 (fr)
JP (1) JP2021501180A (fr)
KR (1) KR20200081443A (fr)
CN (1) CN111527097A (fr)
AU (1) AU2018361991A1 (fr)
CA (1) CA3080128A1 (fr)
IL (1) IL274162A (fr)
WO (1) WO2019089080A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
CA3127113A1 (fr) 2019-01-30 2020-08-06 Dongxu Sun Anticorps anti-gal3 et leurs utilisations
JP2022543666A (ja) 2019-08-09 2022-10-13 イドーシア ファーマシューティカルズ リミテッド （ヘテロ）アリール－メチル－チオ－ベータ－ｄ－ガラクトピラノシド誘導体
WO2021028323A1 (fr) * 2019-08-09 2021-02-18 Idorsia Pharmaceuticals Ltd Dérivés de (2-acétamidyle)thio-bêta-d-galactopyranoside
KR20220047585A (ko) 2019-08-15 2022-04-18 이도르시아 파마슈티컬스 리미티드 2-히드록시시클로알칸-1-카르바모일 유도체
EP4021904B1 (fr) 2019-08-29 2024-01-03 Idorsia Pharmaceuticals Ltd Dérivés d'alpha-d-galactopyranoside
CN115279789A (zh) * 2019-12-06 2022-11-01 真和制药有限公司 破坏gal3和胰岛素受体或整联蛋白的相互作用的抗体及其使用方法
IL301815A (en) 2020-10-06 2023-06-01 Idorsia Pharmaceuticals Ltd Spiro history of alpha-D-galactopyranosides
EP4237419A1 (fr) 2020-11-02 2023-09-06 Idorsia Pharmaceuticals Ltd Dérivés de 2-hydroxycycloalcane-1-carbamoyle inhibant la galectine-3
CN112190590A (zh) * 2020-11-06 2021-01-08 牡丹江医学院 一种治疗动脉粥样硬化的硒核苷及其药物组合物
WO2022171594A1 (fr) 2021-02-09 2022-08-18 Idorsia Pharmaceuticals Ltd Dérivés d'hydroxyhétérocycloalcane-carbamoyle
JP2024509421A (ja) 2021-03-03 2024-03-01 イドルシア・ファーマシューティカルズ・リミテッド トリアゾリル－メチル置換アルファ－ｄ－ガラクトピラノシド誘導体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107406478B (zh) * 2015-01-30 2021-07-27 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
CN105318222B (zh) * 2015-11-13 2018-07-27 南通亚泰蜡业工艺品有限公司 喷泉电子蜡烛
KR102346913B1 (ko) * 2016-03-04 2022-01-04 갈랙틴 사이언시즈, 엘엘씨 갈렉틴과 관련된 질환의 예방 및 치료를 위한 셀레노갈락토시드 화합물 및 이의 용도

Also Published As

Publication number Publication date
KR20200081443A (ko) 2020-07-07
EP3707149A1 (fr) 2020-09-16
AU2018361991A1 (en) 2020-05-14
CN111527097A (zh) 2020-08-11
IL274162A (en) 2020-06-30
WO2019089080A1 (fr) 2019-05-09
JP2021501180A (ja) 2021-01-14
WO2019089080A9 (fr) 2020-07-23

Similar Documents

Publication Publication Date Title
CA3080128A1 (fr) Composes de selenogalactoside pour le traitement de troubles de la resistance systemique a l'insuline et leur utilisation
US20200061095A1 (en) Compounds for the Treatment of Systemic Insulin Resistance Disorders and the Use Thereof
US20230132265A1 (en) Compounds for the prevention and treatment of diseases and the use thereof
US20230127345A1 (en) Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof
CN111032039B (zh) 用于预防和治疗医学障碍的化合物及其用途
JPWO2019140188A5 (fr)